查詢結果分析
相關文獻
- Comparison of Antihypertensive Efficacy and Tolerability of Losartan and Extended-Release Felodipine in Patients with Mild to Moderate Hypertension
- 高血壓藥物治療之現況
- Antihypertensive Effects of AT-112, a Newly Synthesized Quinazoline Derivative, in Spontaneously Hypertensive Rats
- 降高血壓藥物對葡萄糖耐受性之影響
- Antihypertensive and Bilateral Renal Responses to Diuretics in 2-Kidney, 1-Clip Goldblatt Hypertensive Rats
- 高血壓藥物的新選擇--評估Azilsartan Medoxomil的臨床潛在重要性
- 降血壓藥術前是否應持續使用?
- 糖尿病人血壓控制之實證論述
- 使用降血壓藥物之爭議
- 2003年世界衛生組織(WHO)/國際高血壓學會(ISH)對高血壓處置之聲明
頁籤選單縮合
題 名 | Comparison of Antihypertensive Efficacy and Tolerability of Losartan and Extended-Release Felodipine in Patients with Mild to Moderate Hypertension=Losartan及長效型Felodipine在輕度及中度高血壓患者之降血壓效果及耐受性之比較 |
---|---|
作 者 | 洪明銳; 林芬瓊; 程文俊; 王兆弘; 洪國竣; 謝宜璋; 溫明賢; 吳德朗; | 書刊名 | 臺灣醫學會雜誌 |
卷 期 | 98:6 1999.06[民88.06] |
頁 次 | 頁403-409 |
分類號 | 418.221 |
關鍵詞 | 高血壓; 降血壓; 耐受性; Hypertension; Losartan; Felodipine; |
語 文 | 英文(English) |
英文摘要 | Appropriate control of blood pressure has been shown to reduce morbidity and mortality in patients with hypertension. Losartan potassium, a selective antagonist of the angiotensin II type 1 (AT1) receptor, has been shown to lower blood pressure in patients with hypertension. The purpose of this study was to compare the efficacy and tolerability of losartan and extended-release (ER) felodipine in Taiwanese patients with mild to moderate hypertension. Patients with mild to moderate hypertension (sitting diastolic blood pressure, 95-115 mm Hg) were enrolled in this prospective, randomized, parallel study. Sitting blood pressure, heart rate, adverse reactions, and serum biochemistry values were assessed during 2 weeks of placebo and 12 weeks of active treatment. Each patient received 50 mg of losartan or 5 mg of felodipine ER once daily, and the dosage was adjusted to double the initial level at week 6 if necessary. Of the 44 patients randomly allocated to receive losartan (n = 23) or felodipine (n = 21) therapy, 37 completed the study; three patients in the losartan group and four in the felodipine group withdrew because of adverse experiences, or were lost to follow-up. The mean reductions in sitting diastolic blood pressure at 6 and 12 weeks were significant with both losartan (-8.6 and -11.38 mm Hg, respectively) and felodipine (-9.2 and -10.69 mm Hg, respectively), and did not differ significantly between the two groups. Both losartan and ER felodipine were well tolerated by patients. However, the ER felodipine group had a significantly higher rate of drug-related flushing than the losartan group (24% vs 0%, p = 0.022). The results indicate that once-daily administration of losartan is as effective and well tolerated as once-daily ER felodipine in blood pressure reduction. |
本系統中英文摘要資訊取自各篇刊載內容。